Logo

ORMP

Oramed Pharmaceuticals Inc.

ORMP

Oramed Pharmaceuticals Inc. • NASDAQ
$2.85 ▲ 0.00% (+0.00)
Market Cap $118.75 M
52w High $3.09
52w Low $1.82
Dividend Yield 0%
P/E 2.85
Volume 163.00K
Outstanding Shares 41.67M

Income Statement

Period Revenue Operating Expense Net Income Net Profit Margin Earnings Per Share EBITDA
Q2-2025 $0 ▼ $2.489M ▼ $13.288M ▲ 0% ▲ $0.32 ▲ $13.164M ▲
Q1-2025 $2M ▲ $4.513M ▲ $-7.642M ▲ -382.1% ▼ $-0.19 ▲ $-4.47M ▲
Q4-2024 $0 $3.595M ▲ $-10.189M ▲ 0% $-0.26 ▲ $-9.752M ▼
Q3-2024 $0 $3.089M ▼ $-19.619M ▼ 0% $-0.48 ▼ $-3.037M ▼
Q2-2024 $0 $3.135M $9.212M 0% $0.22 $11.153M

Balance Statement

Period Cash & Short-term Total Assets Total Liabilities Total Equity
Q2-2025 $97.94M ▼ $161.684M ▲ $8.101M ▲ $154.529M ▲
Q1-2025 $130.644M ▼ $147.539M ▼ $7.645M ▼ $140.812M ▼
Q4-2024 $141.93M ▼ $155.278M ▼ $9.931M ▲ $146.265M ▼
Q3-2024 $142.3M ▼ $165.081M ▼ $9.559M ▲ $156.441M ▼
Q2-2024 $152.737M $184.223M $8.069M $177.065M

Cash Flow Statement

Period Net Income Cash From Operations Cash From Investing Cash From Financing Net Change Free Cash Flow
Q2-2025 $13.26M ▲ $-3.535M ▼ $-54.853M ▼ $-371K ▼ $-58.719M ▼ $-3.539M ▼
Q1-2025 $-7.642M ▲ $-3.519M ▼ $23.616M ▲ $0 ▲ $20.096M ▲ $-3.522M ▼
Q4-2024 $-10.199M ▲ $-1.911M ▲ $15.424M ▲ $-1.195M ▲ $12.316M ▲ $-1.922M ▲
Q3-2024 $-19.642M ▼ $-7.101M ▼ $-34.26M ▼ $-1.291M ▲ $-42.649M ▼ $-7.106M ▼
Q2-2024 $9.204M $2.076M $94.655M $-30.55M $66.177M $2.076M

Five-Year Company Overview

Income Statement

Income Statement Oramed’s income statement is very simple: it has essentially no product revenue yet and continues to run at a loss, as is common for early‑stage biotech firms. Operating expenses appear relatively contained and have not exploded over the past few years, which suggests some discipline on spending. There was a brief move into profitability in one recent year, but that seems driven by non‑recurring items rather than ongoing business activity. Overall, the profile is: no commercial sales, research and corporate costs steadily exceeding income, and earnings per share that move around but remain fundamentally tied to development progress rather than a mature business model.

Balance Sheet

Balance Sheet The balance sheet shows a small, research‑stage company with modest total assets and no meaningful use of long‑term debt. Equity is the main source of funding, which limits financial leverage risk but means that progress depends heavily on access to capital markets and partnerships. Cash levels have moved up and down over the period but do not show a collapse, indicating the company has so far managed its resources and fundraising reasonably. Still, without revenue, the balance sheet is more a reflection of cash and intellectual property than of hard, cash‑generating assets.

Cash Flow

Cash Flow Cash flow is consistently negative from operations, reflecting ongoing spending on research, clinical work, and overhead with no offsetting product income. The cash burn appears relatively steady rather than sharply accelerating, and there is essentially no meaningful capital expenditure, which is typical for a company whose main asset is intellectual property rather than factories. Free cash flow is therefore negative and depends on periodic infusions from financing or collaborations. The key question for cash flow is not current efficiency, but how long the existing resources and new partnership funding can support the planned clinical programs.

Competitive Edge

Competitive Edge Competitively, Oramed sits in a demanding part of biotech: diabetes, metabolic disease, and related conditions, where enormous, well‑funded players already dominate. Its attempted edge comes from its oral delivery technology for protein drugs, which, if proven, could carve out niches where injections are currently standard. However, the failed late‑stage trial for broad oral insulin significantly weakened its previous moat. The new strategy focuses on narrower patient groups and on partnering through the OraTech joint venture, which could help with manufacturing scale and market access, especially in China. Even with these moves, the company faces intense competition from major pharmaceutical firms developing both injectable and oral versions of similar drug classes, so its position remains fragile and highly dependent on clear, differentiated clinical results.

Innovation and R&D

Innovation and R&D Innovation is the core of Oramed’s story. The POD platform aims to make proteins and peptides—like insulin and GLP‑1 drugs—available in pill form, which is technically challenging but potentially very valuable for patient convenience. The lead oral insulin program suffered a major setback, but the company is trying to “rescue” value by targeting a narrower group of patients who seemed to respond better in post‑hoc analyses. In parallel, Oramed is exploring the same molecule in liver disease (NASH), where early data suggest some biological activity but the field is crowded and difficult. A separate oral GLP‑1 candidate is earlier in development and would enter a space dominated by big pharma if it advances. Overall, the R&D is ambitious and scientifically interesting, but it is still high‑risk, with multiple key programs at stages where failure is common across the industry.

Summary

Oramed is a small, research‑driven biotech at an inflection point. Financially, it has no product revenue, manageable but persistent losses, and a balance sheet that relies on cash, equity, and now a significant partnership rather than debt. Cash burn is steady and tied to clinical progress, making external funding and careful pacing of trials crucial. Strategically, the company is rebuilding after a major clinical failure, shifting from a broad oral insulin play to more targeted indications and leveraging a large joint venture to share costs and commercialization. Its future hinges on whether its oral delivery technology can produce clear, reproducible benefits in specific patient groups and in NASH, and whether it can execute effectively with partners in a market dominated by much larger competitors. The opportunity is substantial if the science works, but the path is narrow and carries the usual high level of uncertainty associated with development‑stage biotech companies.

NEWS

November 17, 2025 · 8:56 AM UTC

Oramed Reports Fiscal Third Quarter 2025 Financial Results

Read more

November 17, 2025 · 8:50 AM UTC

ORAMED PHARMACEUTICALS INC. DECLARES DIVIDEND DISTRIBUTION OF COMMON STOCK PURCHASE RIGHTS

Read more

October 23, 2025 · 8:55 AM UTC

Oramed Releases Letter to Shareholders, Highlighting Developments in its Oral Insulin Program, Significant Investment Appreciation, and Upcoming Growth Initiatives

Read more